Durable clinical, cytogenetic, and molecular remissions after allogeneic hematopoietic cell transplantation for refractory sezary syndrome and mycosis fungoides

Journal of Clinical Oncology

Volumn 23, Issue 25, 2005, Pages 6163-6171

  Molina, Arturo ^a   Zain, Jasmine ^a   Arber, Daniel A ^a   Angelopolou, Maria ^a   O'Donnell, Margaret ^a   Murata Collins, Joyce ^a   Forman, Stephen J ^a   Nademanee, Auayporn ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; BEXAROTENE; BUSULFAN; CHLORMETHINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DENILEUKIN DIFTITOX; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GAMMA INTERFERON; GEMCITABINE; ISOTRETINOIN; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTOSTATIN; ANTINEOPLASTIC AGENT;

ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER STAGING; CELL CLONING; CELL POPULATION; CHROMOSOME TRANSLOCATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOGENETICS; FEMALE; FOLLOW UP; GENE REARRANGEMENT; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; MALE; MYCOSIS FUNGOIDES; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PUVA; SEZARY SYNDROME; T LYMPHOCYTE; T LYMPHOCYTE RECEPTOR GENE; VIRUS PNEUMONIA; WHOLE BODY RADIATION; ALLOTRANSPLANTATION; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; KARYOTYPING; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BUSULFAN; CYCLOPHOSPHAMIDE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KARYOTYPING; MALE; MIDDLE AGED; MYCOSIS FUNGOIDES; RETROSPECTIVE STUDIES; SEZARY SYNDROME; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; WHOLE-BODY IRRADIATION;

EID: 24944576742     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.02.774     Document Type: Article

References (40)

1. Diamandidou E, Cohen PR, Kurzrock R: Mycosis fungoides and Sezary syndrome. Blood 88:2385-2409, 1996
2. Kim YH, Hoppe RT: Mycosis fungoides and the Sezary syndrome. Semin Oncol 26:276-289, 1999
3. Koh HK, Charif M, Weinstock MA: Epidemiology and clinical manifestations of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 9:943-960, 1995
4. Kim YH, Bishop K, Varghese A, et al: Prognostic factors in erythrodermic mycosis fungoides and the Sezary syndrome. Arch Dermatol 131:1003-1008, 1995
5. Lim H, Edelson RL: Photopheresis for the treatment of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 9:1117-1126, 1995
6. Molina A, Sniecinski I, Forman SJ: Extracorporeal photochemotherapy (ECP) in combination with interferon alpha (INF-α): An effective treatment for advanced mycosis fungoides/cutaneous T-cell lymphoma (MF/CTCL). Blood 82:145a, 1993 (suppl 1, abstr 564)
7. Duvic M, Hymes K, Heald P, et al: Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: Multinational Phase II-III trial results. J Clin Oncol 19:2456-2471, 2001
8. Olsen E, Duvic M, Frankel A, et al: Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 19:376-388, 2001
9. Lundin J, Hagberg H, Repp R, et al: A phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood 101:4267-4272, 2003
10. Molina A, Nademanee A, Arber D, et al: Remission of refractory Sezary syndrome after bone marrow transplantation from a matched unrelated donor. Biol Blood Marrow Transplant 5:400-404, 1999
11. Burt RK, Guitart J, Traynor A, et al: Allogeneic hematopoietic transplantation for advanced mycosis fungoides: Evidence for a graft-versus-tumor effect. Bone Marrow Transplant 25:111-113, 2000
12. Masood N, Russell KJ, Olerud JE, et al: Induction of complete remission of advanced stage mycosis fungoides by allogeneic hematopoietic stem cell transplantation. J Am Acad Dermatol 47:140-145, 2002
13. Guitart J, Wickless SC, Oyama Y, et al: Long-term remission after allogeneic hematopoietic stem cell transplantation for refractory cutaneous T-cell lymphoma. Arch Dermatol 138: 1359-1365, 2002
14. Soligo D, Ibatici A, Berti E, et al: Treatment of advanced mycosis fungoides by allogeneic stem cell transplantation with a non-myeloablative regimen. Bone Marrow Transplant 31:663-666, 2003
15. Sausville EA, Eddy JL, Makuch RW, et al: Histopathologic staging at initial diagnosis of mycosis fungoides and the Sezary syndrome: Definition of three distinctive prognostic groups. Ann Intern Med 109:372-382, 1988
16. Giralt S, Thall PF, Khouri I, et al: Melphalan and purine analog-containing preparative regimens: Reduced intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 97:631-637, 2001
17. Giralt S, Aleman A, Anagnostopoulos A, et al: Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma. Bone Marrow Transplant 30:367-373, 2002
18. Nademanee A, Schmidt GM, Parker PM, et al: The outcome of matched unrelated donor bone marrow transplantation in patients with hematologic malignancies utilizing molecular typing for donor selection and graft versus host disease prophylaxis regimen of cyclosporine, methotrexate and prednisone. Blood 86:1228-1234, 1995
19. Chao NJ, Schmidt GM, Niland JC, et al: Cyclosporine, methotrexate and prednisone compared to cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. N Engl J Med 329:1225-1230, 1993
20. Bornhauser M, Schuler U, Porksen G, et al: Mycophenolate mofetil and cyclosporine as graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation. Transplantation 67:499-504, 1999
21. Blume KG, Forman SJ, Appelbaum FR: Thomas' Hematopoietic Cell Transplantation (ed 3). Malden, MA, Blackwell Scientific Publications, 2004
22. Borowitz MJ, Guenther KL, Shuts KE, et al: Immunophenotyping of acute leukemia by flow cytometric analysis: Use of CD45 and right-angle light scatter to gate on leukemic blasts in three-color analysis. Am J Clin Pathol 100:534-540, 1993
23. Thangavelu M, Finn WG, Yelavarthi KK, et al: Recurring structural chromosome abnormalities in peripheral blood lymphocytes of patients with mycosis fungoides/sezary syndrome. Blood 89:3371-3377, 1997
24. Mitelman F (ed): ISCN (1995): An International System for Human Cytogenetics Nomenclature. Basel, Switzerland, S Karger AG, 1995
25. Greiner TC, Raffeid M, Lutz C, et al: Analysis of T cell receptor-γ gene rearrangements by denaturing gradient gel electrophoresis of GC-clamped polymerase chain reaction products: Correlation with tumor specific sequences. Am J Pathol 146:46-55, 1995
26. Fraser-Andrews EA, Woolford AJ, Seed PT, et al: Detection of a peripheral blood T-cell clone is an independent prognostic marker in mycosis fungoides. J Invest Dermatol 114:117-121, 2000
27. Liu X, Chesnokova V, Forman SJ, et al: Molecular analysis of T-cell receptor repertoire in bone marrow transplant recipients: Evidence for oligoclonal T-cell expansion in graft-versus-host disease lesions. Blood 87:3032-3044, 1996
28. Bigler RD, Crilley P, Micaily B, et al: Autologous bone marrow transplantation for advanced mycosis fungoides. Bone Marrow Transplant 7:133-137, 1991
29. Sterling JC, Marcus R, Burrows NP, et al: Erythrodermic mycosis fungoides treated with total body irradiation and autologous bone marrow transplantation. Clin Exp Dermatol 20:73-75, 1995
30. Olavarria E, Child F, Woolford A, et al: T-cell depletion and autologous stem cell transplantation in the management of tumour stage mycosis fungoides with peripheral blood involvement. Br J Haematol 114:624-631, 2001
31. Jones RJ, Ambinder RF, Piantadosi S, et al: Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood 77:649-653, 1991
32. Lundberg JH, Hansen RM, Chitambar CR, et al: Allogeneic bone marrow transplantation for relapsed and refractory lymphoma using genotypically HLA-matched and alternative donors. J Clin Oncol 9:1848-1849, 1991
33. Marolleau JP, Baccard M, Flageul G, et el. High-dose recombinant interleukin-2 in advanced cutaneous T-cell lymphoma. Arch Dermatol 131: 574-579, 1995
34. Rook AH, Wood GS, Yoo EK: Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses. Blood 94:902-908, 1999
35. Foss FM, Ihde DC, Breneman DL, et al: Phase II study of pentostatin and intermittent high-dose recombinant interferon alfa-2a in advanced mycosis fungoides/Sezary syndrome. J Clin Oncol 10:1907-1913, 1992
36. Rodriguez R, Parker P, Nademanee A, et al: Cyclosporine and mycophenolate mofetil prophylaxis with fludarabine and melphalan conditioning for unrelated donor transplantation: A prospective study of 22 patients with hematologic malignancies. Bone Marrow Transplant 33: 1123-1129, 2004
37. Van Besien KW, Khouri IF, Giralt SA, et al: Allogeneic bone marrow transplantation for refractory and recurrent low grade lymphoma: The case for aggressive management. J Clin Oncol 13:1096-1102, 1995
38. Dann EJ, Daugherty CK, Larson RA: Allogeneic bone marrow transplantation for relapsed and refractory Hodgkin's disease and non-Hodgkin's lymphoma. Bone Marrow Transplant 20:369-374, 1997
39. Bierman P, Molina A, Nelson G, et al: Matched unrelated donor (MUD) allogeneic bone marrow transplantation for non-Hodgkin's lymphoma (NHL): Results from the National Marrow Donor Program (NMDP). Proc Amer Soc Clin Oncol 18:3a, 1999 (abstr 7).
40. Molina A, Nademanee A, Palmer JC, et al: Allogeneic hematopoietic stem cell transplantation (ALLO HSCT) for poor-risk non-Hodgkin's lymphoma (NHL): The City of Hope (COH) experience. Proc Amer Soc Clin Oncol 19:19a, 2000 (abstr 65)